ProCE Banner Activity

Phase III QuANTUM-First: Prognostic Value of FLT3-ITD–Specific MRD Clearance at Induction/Consolidation Using Chemotherapy With or Without Quizartinib in Patients With AML

Conference Coverage
Slideset

In this analysis of the phase III QuANTUM-First study, findings demonstrated that reduction in FLT3-ITD–specific MRD is prognostic for overall survival in patients with FLT3-ITD+ AML, with quizartinib associated with deeper responses.

Released: December 15, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.